Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The market tendencies for Juvenile Macular Degeneration (JMD) are extensively motivated by the growing prevalence of this condition among young people. Improved diagnostic techniques and multiplied focus have caused an early and accurate analysis, driving the demand for effective treatments. A key motive force inside the market is the continuous progress in research and development. Pharmaceutical companies are investing closely in innovative cures and pills to cope with the specific challenges posed by using Juvenile Macular Degeneration. These improvements maintain the promise of improved consequences for sufferers, fostering a competitive panorama. The market is witnessing a shift in the direction of various therapeutic approaches, starting from gene treatment options to regenerative remedies.
Biotechnological breakthroughs, in particular in the discipline of gene editing and gene therapy, are revolutionizing the JMD market. These technologies are beginning to open up new possibilities for treating the situation at its root cause, leading to a surge in studies, collaborations, and partnerships inside the biotech industry. The market is increasingly specializing in affected person-centric care, with a developing emphasis on enhancing the first-class of life for individuals tormented by Juvenile Macular Degeneration. Patient advocacy businesses and aid networks play an essential position in shaping market tendencies by influencing treatment preferences and elevating awareness. Collaboration on an international scale is a prominent trend as stakeholders apprehend the importance of shared assets and understanding.
The accessibility and affordability of treatments remain essential factors influencing market dynamics. Efforts to streamline regulatory procedures and increase coverage insurance for Juvenile Macular Degeneration cures are pivotal in ensuring that those improvements attain a broader populace. Rising awareness campaigns, driven by using each governmental and non-governmental company, are contributing to early detection and intervention. Educational tasks are vital in reducing the stigma related to vision-associated problems, encouraging individuals to search for clinical interest right away. The aggressive landscape of the JMD market is evolving hastily, with several gamers vying for market share. Established pharmaceutical organizations, as well as startups, are actively engaged in the improvement and commercialization of novel therapies, intensifying competition and fostering innovation.
Juvenile Macular Degeneration Market Highlights:
Juvenile Macular Degeneration Market Overview :
Juvenile Macular Degeneration (Stargardt Disease) Market Size was valued at USD 1.44 Billion in 2023. The Global Juvenile Macular Degeneration (Stargardt Disease) industry is projected to grow from USD 1.52 Billion in 2024 to USD 1.85 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.36% during the forecast period (2024 - 2032).
Juvenile macular degeneration is a genetic eye disorder that causes progressive vision loss. This disorder affects the retina, the specialized light-sensitive tissue that lines the back of the eye. Specifically, juvenile macular degeneration affects a small area near the center of the retina called the macula. The macula is responsible for sharp central vision, which is needed for detailed tasks such as reading, driving, and recognizing faces. The market is mainly driven by factors such as the increasing prevalence of eye disorders, development of new drugs and therapies, and emerging government policies. However, the high cost of treatment and lack of reimbursement is expected to restrain the growth of this market.
Market Dynamics
The rising prevalence of eye disorder and technological advancements in juvenile macular degeneration are some of the factors that drive the growth of the market. Juvenile macular degeneration is a rare inherited eye condition which affects the central area of the retina called the macula, also known as fundus flavimaculatus. It affects about 1 in 10,000 people and is sometimes called juvenile macular dystrophy since it tends to first appear between the ages of 10 to 20 although visual impairment may not be apparent until as late as ages 30 to 40. Juvenile macular degeneration disease causes parts of the macula to stop working, leading to problems with central vision, detailed vision, and sometimes with color perception. The major driving factors for the global juvenile macular degeneration market are increasing the prevalence of eye disorders, development of new drugs, and therapies, and emerging government policies. However, lack of awareness and no treatment option for juvenile macular dystrophy may hamper the market growth.
Global Juvenile Macular Degeneration (Stargardt Disease) Market Size, by Diagnosis, 2016 and 2027 (USD Million) 
Source: MRFR Analysis
Segmentation
The global juvenile macular degeneration (Stargardt disease) market has been segmented into diagnosis, management, and end user. Based on the diagnosis, the market has been segregated into fluorescein angiography (FA), fundus autofluorescence (FAF), optical coherence tomography (OCT), and electroretinography (ERG). The FA segment accounted for a market value of USD 270.110 million in 2016. Based on management, the market has been segregated into magnifying spectacles, magnifiers, and reading telescopes. The global juvenile macular degeneration (Stargardt disease) market on the basis of end-user is divided into hospital & eye clinics, and research & academic institutes.
Key Players
The prominent players in the global juvenile macular degeneration (Stargardt disease) market are Astellas Pharma Inc (Japan), Sanofi (France), Acucela Inc (Japan), Alkeus Pharma (US), Copernicus Therapeutics (US), Ophthotech Corporation (US), Bayer AG (Germany), Oxford BioMedica PLC (UK), and Grupo Ferrer (Spain).
Some of the key strategies followed by the players operating in the global juvenile macular degeneration (Stargardt disease) market were innovation, product development, acquisition, mergers, and expansion.
Global Juvenile Macular Degeneration (Stargardt Disease) Market Share, by Region, 2016 (%) 
Source: MRFR Analysis
Regional Analysis
The global juvenile macular degeneration (Stargardt disease) market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
Europe accounted for the significant share in the market for juvenile macular degeneration. Rising investment in research & development, well-developed healthcare infrastructure, and increasing healthcare funds are some of the factors responsible for boosting the growth of the market in this region. Europe held the most significant market share of 32.7 % in 2016.
Americas is estimated to be the second-largest market. This is attributed due to the well-developed technology, rising healthcare expenditure, and the presence of the leading players in the market.
Asia-Pacific is projected to be the fastest-growing market due to the rising aging population, increasing healthcare expenditure, and rapidly changing healthcare sector. In addition to this, improving healthcare facilities and rising economic growth is positively impacting the market growth in this region.
The market in the Middle East & Africa is expected to witness steady growth due to increasing investments in research & development, well-developed infrastructure, and advancement in technology.
Key Updates
- In November 2017, Astellas Pharma Inc launched “Repatha” a human monoclonal antibody for the treatment of hypercholesterolemia.
- In December 2017, Sanofi acquired Protein Science company in order to expand its product portfolio.
- In January 2017, Acucela Inc received orphan drug approval for treatment of Stargardt disease. Hence this product approval will help the company to increase its revenue in the future as very few drugs are available for the treatment of Stargardt disease.
Market Segmentation
Global Juvenile Macular Degeneration (Stargardt Disease) Market, by Diagnosis
- Fluorescein Angiography (FA)
- Fundus Autofluorescence (FAF)
- Optical Coherence Tomography (OCT)
- Electroretinography (ERG)
Global Juvenile Macular Degeneration (Stargardt Disease) Market, by Management
- Magnifying Spectacles
- Magnifiers
- Reading telescopes
Global Juvenile Macular Degeneration (Stargardt Disease) Market, by End-User
- Hospital & Eye Clinics
- Research & Academic Institutes
Global Juvenile Macular Degeneration (Stargardt Disease) Market, by Region
- Americas
- North America
- US
- Canada
- Latin America
- North America
- Europe
- Western Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Western Europe
- Eastern Europe
- Western Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- Middle East
- Africa
Available Additional Customizations
Intended Audience
- Medical device manufacturers and distributors
- Government research organizations
- Hospitals and clinics
- Regulatory agencies
- Contract research organizations
- Pharmaceutical companies
- Medical research laboratories
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
